AngioLab Inc
251280
Company Profile
Business description
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.
Contact
65 Techno 3ro
Suite 159
Hanshin S Mecca
Yuseong-gu
Doejeon
CHNT: +86 428675785
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,959.70 | 106.00 | 1.35% |
| CAC 40 | 7,273.12 | 168.32 | 2.37% |
| DAX 40 | 20,954.83 | 580.73 | 2.85% |
| Dow JONES (US) | 40,543.07 | 330.36 | 0.82% |
| FTSE 100 | 8,134.34 | 170.16 | 2.14% |
| HKSE | 21,417.40 | 502.71 | 2.40% |
| NASDAQ | 16,831.48 | 107.02 | 0.64% |
| Nikkei 225 | 33,982.36 | 396.78 | 1.18% |
| NZX 50 Index | 12,107.54 | 88.41 | 0.74% |
| S&P 500 | 5,408.70 | 45.34 | 0.85% |
| S&P/ASX 200 | 7,748.60 | 102.10 | 1.34% |
| SSE Composite Index | 3,262.81 | 24.58 | 0.76% |